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Abstract
Background and objectives This analysis from theNephrotic Syndrome StudyNetwork (NEPTUNE) assessed the
phenotypic and pathology characteristics of proteinuric patients undergoing kidney biopsy and defined the
frequency and factors associated with complete proteinuria remission (CRever).
Design, setting, participants, & measurementsWe enrolled adults and children with proteinuria$0.5 g/d at the
time of first clinically indicated renal biopsy at 21 sites in North America from April 2010 to June 2014 into a
prospective cohort study. NEPTUNE central pathologists assigned participants to minimal-change disease
(MCD), FSGS, membranous nephropathy, or other glomerulopathy cohorts. Outcome measures for this analysis
were (1) CReverwith urine protein-to-creatinine ratio (UPC),0.3 g/gwith preserved native kidney function and
(2) ESRD. Continuous variables are reported as median and interquartile range (IQR; 25th, 75th percentile). Cox
proportional hazards modeling was used to assess factors associated with CRever.
Results We enrolled 441 patients: 116 (27%) had MCD, 142 (32%) had FSGS, 66 (15%) had membranous
nephropathy, and 117 (27%) had other glomerulopathy. The baseline UPC was 4.1 g/g (IQR, 1.9, 7.7) and the
eGFR was 81 ml/min per 1.73 m2 (IQR, 50, 105). Median duration of observation was 19 months (IQR, 11, 30).
CRever occurred in 46% of patients, and 4.6% progressed to ESRD. Multivariate analysis demonstrated that
higher prebiopsy proteinuria (hazard ratio, 0.3; 95% confidence interval, 0.2 to 0.5) and pathology diagnosis
(FSGS versusMCD; hazard ratio, 0.2; 95% confidence interval, 0.1 to 0.5) were inversely associated with CRever.
The effect of immunosuppressive therapy on remission varied by pathology diagnosis.
Conclusions In NEPTUNE, the high frequency of other pathology in proteinuric patients affirms the value of the
diagnostic kidney biopsy. Clinical factors, including level of proteinuria before biopsy, pathology diagnosis, and
immunosuppression, are associated with complete remission.
Clin J Am Soc Nephrol 11: 81–89, 2016. doi: 10.2215/CJN.02560315
Introduction
Primary noninflammatory glomerular diseases, in-
cluding minimal-change disease (MCD), FSGS, and
membranous nephropathy (MN), account for 12% of
prevalent ESRD at an annual cost of $3 billion in the
United States (1). The major goal of the Nephrotic
Syndrome Study Network (NEPTUNE) is to assem-
ble an observational cohort with MCD, FSGS, and
MN to support innovative multidisciplinary transla-
tional research and advance the field toward effective
treatments (2,3). Here, we describe baseline cohort
characteristics, early disease outcomes, and address
the following questions: (1) What are the characteristics
of proteinuric patients undergoing kidney biopsy in
North America today? and (2) What are the factors
associated with the short-term outcome of complete
proteinuria remission (CRever)?
Materials and Methods
Following institutional review board approval and
patient/guardian consent and minor assent, eligible
patients were enrolled in the NEPTUNE longitudinal
cohort study at the time of clinically indicated initial
kidney biopsy. Full details of the study design have
been published elsewhere (2,3). Eligibility criteria in-
clude individuals of any age scheduled for a clinically












Ann Arbor, MI 48109.
Email: dgipson@med.
umich.edu
Any exposure to immunosuppression therapy (IST) and
renin-angiotensin-aldosterone-system (RAAS) blockade for
treatment of kidney disease before or after study entry was
captured. IST included steroids, calcineurin inhibitors,
cyclophosphamide, mycophenolate mofetil, and rituximab.
CRever, defined as UPC,0.3 g/g with preserved native
kidney function during at least one visit in the prospective
observation, served as the primary outcome for this
analysis and was restricted to patients with at least one
follow-up proteinuria measurement. ESRD was defined as
initiation of long-term dialysis, kidney transplant, or
eGFR,15 ml/min per 1.73 m2 on two consecutive study
visits. The eGFR was estimated using the Chronic Kidney
Disease–Epidemiology Collaboration equation for adults
age 18 years and older and the Chronic Kidney Disease
in Children–Schwartz formula for children (5,6).
Statistical Analyses
Analyses were conducted using SAS software, version
9.2. Baseline characteristics of the sample were described
using frequencies and percentages for categorical variables
and medians and interquartile ranges (IQRs; 25th, 75th
percentiles) for continuous variables. The distribution
of variables of interest was compared across three UPC
categories (,1, 1–3, and .3 g/g) using chi-squared tests
for categorical variables and Kruskal–Wallis tests for con-
tinuous variables.
Time to first complete remission was analyzed by Cox
proportional hazards models. The main covariate of in-
terest was initial UPC category (, 1, 1–3, or .3 g/g). Im-
munosuppressive exposure was characterized by two
variables measuring exposure to IST before and after the
baseline visit. Effect modification corresponding to the ef-
fect of treatment by cohort was assessed by interaction
terms. The inclusion criterion in backward selection was
set at a,0.25. Covariates were then removed from the Cox
model at a significance level of a,0.05.
Results
As of December 1, 2014, 554 patients were enrolled into
the NEPTUNE study. Sixty-two participants were excluded
on the basis of ineligible kidney biopsy showing systemic
or secondary disease (diabetic nephropathy [n=16 (26%)],
lupus nephritis [n=3 (5%)], amyloidosis [n=7 (11%)],
Alport syndrome [n=1 (2%)], insufficient biopsy material
for pathology classification [n=8 (13%)], and pending bi-
opsy review [n=27 patients (44%)]). Fourteen patients were
excluded because of a previous biopsy. In addition, with-
drawal before biopsy or completing enrollment (n=32) and
ESRD at baseline (n=5) contributed to a total 113 ineligible
participants (Figure 1).
Baseline characteristics of the 441 eligible and active
patients are summarized in Table 1. Patients range in age
from 1 to 84 years; 66% were adults (age $18 years) at the
time of biopsy. Of the patients, 24% were black, 14% were
Asian, 57% were white, 5% were multiracial, and 21%
were Hispanic. Median baseline UPC was 4.1 g/g (IQR,
1.9, 7.7; range, 0.1–59.8), and eGFR was 81 ml/min per
1.73 m2 (IQR, 50, 105; range, 7.1–237.1). A total of 33%
reported a family history of kidney disease, including 19
(4%) with ESRD. More than 50% reported a family history
indicated initial renal biopsy with proteinuria $0.5 g/d 
from 24-hour urine or .0.5 g/g random urine protein-
to-creatinine ratio (UPC). Patients with subnephrotic pro-
teinuria were included to capture the broad spectrum of 
clinical presentations of MCD, FSGS, and MN. Exclusion 
criteria included patients with clinical or pathologic evi-
dence of other kidney diseases (e.g., systemic diseases, 
such as diabetic nephropathy, systemic lupus erythemato-
sus, vasculitis, Alport syndrome, amyloidosis, and mono-
clonal gammopathy), prior solid organ transplant, life 
expectancy ,6 months, and unwillingness or inability to 
consent. The enrollment goal was 450 participants, with a 
recruit-to-replace strategy to achieve and maintain 450 ac-
tive participants.
Study visits included screening/biopsy/baseline (which 
could occur simultaneously or sequentially), then every 
4 months in year 1  and every 6 months thereafter.  
Observation is ongoing. Initial data capture included 
demographic characteristics; social, medical, and family 
history; past therapy for nephrotic syndrome; patient-
reported outcome; and results of local clinical laboratories. 
Urine and blood biosamples collected in the baseline and 
follow-up study visits were used for this analysis. The local 
biopsy report was masked for identifiers and submitted for 
core review. Digital images of stained slides are being 
acquired, stored in the NEPTUNE digital pathology re-
pository, and reviewed. This digital review is not yet 
complete for all participants reported in this article. The 
determination of pathology cohort assignment was initially 
made by review of the local pathology report by one 
member of the NEPTUNE pathology committee. Where 
digital images were available, additional detailed pathol-
ogy image review was completed by a minimum of two 
members of the NEPTUNE pathology committee to con-
firm cohort assignment as MCD, FSGS, MN, or other (3). 
Cases in which light microscopy showed minimal lesions 
and immunofluorescence and electron microscopy did not 
reveal other conditions were assigned to the MCD cohort. 
On the basis of pathology review and laboratory data 
available following enrollment, patients meeting exclusion 
criteria were unenrolled.
Eligibility urine protein measurements were abstracted 
from the local patient medical record. Following enrollment, 
urine samples were collected at each study visit and assayed 
in the central laboratory. The 24-hour urine protein and 
creatinine measures were preferentially used for UPC values 
in this study. When 24-hour urine specimens were unavail-
able, random urine samples were used. Urine protein was 
measured via colorimetric dye binding assay and urine 
creatinine was measured via immunoturbidimetric assay 
at the urine laboratory at Mayo Clinic, Rochester, MN. Se-
rum samples were assayed for creatinine (using the enzy-
matic Jaffe method) and for cholesterol, triglycerides, and 
HDL (by the Cobas Mira Plus chemistry analyzer, Roche, 
Inc.) at the Michigan Diabetes Research and Training Cen-
ter laboratory at the University of Michigan. LDL was cal-
culated using the following equation: LDL cholesterol=total 
cholesterol2HDL2(triglycerides/5) (4). Patients were di-
vided into three categories based on the earliest reported 
proteinuria value collected at the eligibility assessment: 
UPC,1 g/g, UPC 1–3 g/g, and UPC.3 g/g.
of hypertension, and 39% reported a family history of di-
abetes. Disease duration did not significantly differ be-
tween children and adults: 4 months (IQR, 1, 15) versus
4 months (IQR, 1, 24) (P=0.87).
Previous Immunosuppression and RAAS Blockade
A total of 196 (44%) of patients were exposed to IST
before their baseline visit: 188 (43%) exposed to steroids, 52
(12%) to calcineurin inhibitors, 19 (4%) to cyclophospha-
mide, 28 (6%) to mycophenolate mofetil, and two (1%) to
rituximab. There were also 278 patients (63%) who had
been previously treated with RAAS blockade.
Proteinuria Classification
At study eligibility assessment, 50 (11%) patients had a
UPC,1 at enrollment, 125 (28%) had a UPC of 1–3, and
266 (60%) had a UPC.3 g/g (Table 1). Patients with the
lowest level of proteinuria were equally likely to have
FSGS, MCD, or other diagnosis. Those with MCD and
UPC,1 g/g (n=15) included five children with prebaseline
IST and nine individuals ranging in age between 9 and 51
years without prebaseline IST. The eGFR in the group with
MCD and a UPC,1 g/g was well preserved at 96 ml/min
per 1.73 m2 (IQR, 81, 105). Conversely, the eGFR of the
FSGS and UPC,1 g/g group was 77 ml/min per 1.73 m2
(IQR, 56, 103). Patients with nephrotic-range proteinuria
(UPC.3 g/g) were more likely to have had a short
Table 1. Nephrotic Syndrome Study Network baseline characteristics by urine protein-to-creatinine ratio
Characteristics All UPC,1 g/g UPC 1–3 g/g UPC.3 g/g P Value
All participants 441 50 (11) 125 (28) 266 (60) ,0.001
Female patients 180 (41) 18 (36) 46 (37) 116 (44) 0.34
Age, y 31 (14, 52) 26 (15, 47) 30 (15, 47) 33 (14, 55) 0.50
Race 0.03
Asian 55 (14) 6 (13) 19 (16) 30 (13)
Black 97 (24) 10 (22) 41 (34) 46 (19)
White 229 (57) 27 (60) 52 (44) 150 (63)
Multiracial 22 (5) 2 (4) 7 (6) 13 (5)
Hispanic 88 (21) 8 (17) 23 (19) 57 (23) 0.49
Disease duration, mo 4 (1, 18) 8 (2, 34) 7 (2, 27) 2 (1, 10) ,0.001
Preterm birth 36 (9) 2 (4) 14 (12) 20 (8) 0.27
Weight status 0.66
Overweight 114 (28) 11 (26) 38 (31) 65 (27)
Obese 158 (39) 14 (33) 47 (39) 97 (41)
Family history of kidney disease 140 (33) 15 (32) 38 (31) 87 (35) 0.79
Hypertension 121 (30) 6 (14) 36 (30) 79 (33) 0.15
UPC, g/g 4.1 (1.9, 7.7) 0.6 (0.5, 0.8) 1.9 (1.4, 2.4) 6.8 (4.7, 10.4) ,0.001
Edema 168 (42) 16 (37) 29 (24) 123 (51) ,0.001
eGFR, ml/min per 1.73 m2 81 (50, 105) 92 (67, 105) 83 (46, 107) 77 (48, 103) 0.12
Albumin, g/dl 3.3 (2.5, 4.0) 4.2 (3.5, 4.4) 3.9 (3.2, 4.3) 2.9 (2.2, 3.5) ,0.001
Cholesterol, mg/dl 237 (191, 310) 203 (164, 234) 213 (180, 246) 266 (210, 350) ,0.001
LDL cholesterol, mg/dl 134 (95, 188) 102 (85, 152) 113 (81, 149) 155 (105, 215) ,0.001
Cohort ,0.001
FSGS 142 (32) 16 (32) 49 (39) 77 (29)
MCD 116 (26) 15 (30) 19 (15) 82 (31)
MN 66 (15) 3 (6) 12 (10) 51 (19)
Other 117 (27) 16 (32) 45 (36) 56 (21)
Prior medication exposure
IST 196 (44) 12 (24) 36 (29) 148 (56) ,0.001
RAAS blockade 278 (63) 28 (56) 93 (74) 157 (59) 0.01
Prior IST duration, mo 1 (0, 5) 2 (0, 4) 2 (0, 8) 1 (0, 5) 0.81
Categorical variables are reported as frequencies and percentages, and P values were estimated using a chi-squared test. Continuous
variables are reported as medians and interquartile ranges, and P values were generated using a Kruskal–Wallis test. Prior medication
exposure refers to medications reported before study baseline visit. UPC, urine protein-to-creatinine ratio; MCD, minimal-change
disease; MN, membranous nephropathy; IST, immunosuppressive therapy; RAAS, renin-angiotensin-aldosterone system.
Figure 1. | Participant disposition in the Nephrotic Syndrome Study
Network. The most common reasons for study ineligibility pertained
to the kidney biopsy eligibility criteria.
duration of disease before biopsy and to have edema (51%)
and a history of IST. They were also more likely to have
MCD (31%) or FSGS (29%) than MN (19%) or other diag-
nosis (21%) on biopsy (P,0.001).
Renal Pathology
NEPTUNE patient pathology included MCD (n=116
[27%]), FSGS (n=142 [32%]), MN (n=66 [15%]), and other
diagnosis (n=117 [27%]) (Table 2). The distribution of
Table 2. Nephrotic Syndrome Study Network baseline characteristics by pathology
Characteristics MCD FSGS MN Other P Value
All participants 116 142 66 117 ,0.001
Female patients 51 (44) 58 (41) 26 (40) 45 (38) 0.85
Age, y 12 (6, 27) 33 (16, 49) 54 (40, 62) 36 (18, 48) ,0.001
Race ,0.001
Asian 14 (13) 13 (10) 4 (6) 24 (23)
Black 25 (24) 46 (35) 9 (15) 17 (16)
White 56 (53) 66 (50) 46 (74) 61 (58)
Multiracial 10 (10) 6 (5) 3 (5) 3 (3)
Hispanic 20 (18) 30 (22) 11 (17) 27 (25) 0.87
Disease duration, mo 4 (1, 14) 4 (1, 36) 3 (0, 9) 4 (1, 13) 0.42
Preterm birth 12 (11) 15 (11) 1 (2) 8 (7) 0.11
Weight status 0.03
Overweight 28 (27) 35 (26) 17 (27) 34 (33)
Obese 28 (27) 61 (46) 31 (50) 38 (37)
Family history of kidney disease 29 (26) 52 (38) 21 (33) 38 (35) 0.30
Hypertension 35 (34) 44 (33) 12 (19) 30 (29) 0.28
Edema 42 (41) 50 (37) 42 (68) 34 (32) ,0.001
eGFR, ml/min per 1.73 m2 105 (85, 125) 61 (42, 92) 82 (66, 98) 64 (38, 97) ,0.001
Albumin, g/dl 2.9 (2.1, 4.0) 3.5 (2.8, 4.1) 2.7 (2.3, 3.1) 3.6 (3.0, 4.1) ,0.001
Cholesterol, mg/dl 245 (201, 384) 236 (181, 290) 277 (243, 348) 213 (179, 251) ,0.001
LDL cholesterol, mg/dl 141 (97, 215) 123 (87, 184) 157 (126, 218) 116 (83, 154) ,0.001
Indication for biopsy ,0.001
Proteinuria 59 (51) 83 (58) 48 (72) 78 (67)
Decreased kidney function 7 (6) 40 (28) 8 (12) 21 (18)
SDNS/FRNS 33 (28) 6 (4) 1 (2) 4 (3)
SRNS 11 (9) 4 (3) 0 (0) 1 (1)
Other 6 (5) 9 (6) 9 (14) 13 (11)
Eligibility UPC, g/g 6.3 (2.5, 10.8) 3.7 (1.8, 6.6) 5.5 (3.1, 8.6) 2.8 (1.0, 5.0) ,0.001
Prior medication exposure
IST 89 (76) 50 (35) 16 (25) 41 (35) ,0.001
RAAS blockade 39 (33) 100 (70) 55 (85) 84 (72) ,0.001
Prior IST duration, mo 2 (0, 8) 0.1 (0.1, 4) 0.25 (0, 2) 0.5 (0, 2) 0.03
Categorical variables are reported as frequencies and percentages, and P values were obtained using a chi-squared test. Continuous
variables are reported as medians and interquartile ranges, and P values were generated using a Kruskal–Wallis test. Prior medication
exposure refers to medications reported before study baseline visit. SDNS, steroid-dependent nephrotic syndrome; FRNS, frequently
relapsing nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; UPC, urine protein-to-creatinine ratio; IST, immuno-
suppressive therapy; RAAS, renin-angiotensin-aldosterone system; MCD, minimal-change disease; MN, membranous nephropathy.
Figure 2. | Distribution of glomerulopathies in the Nephrotic Syndrome Study Network cohort by age (in years) at enrollment. Minimal-
change disease (MCD) was most common in younger ages, membranous nephropathy (MN) was primarily present in adults, and FSGS and
other glomerulopathies were present in all ages.
Table 3. Complete remission ever compared with persistent proteinuria in the Nephrotic Syndrome Study Network cohort
Variable Persistent Proteinuria Complete Remission Ever P Value
All participants 225 (54) 188 (46)
Female 97 (43) 70 (37) 0.23
Age, y 37 (18, 52) 19 (11, 51) ,0.001
Race 0.02
Asian 33 (16) 20 (11)
Black 60 (28) 31 (18)
White 110 (52) 112 (64)
Multiracial 9 (4) 13 (7)
Hispanic 50 (23) 35 (19) 0.57
Disease duration, mo 4 (1, 24) 4 (1, 12) 0.37
Preterm birth 23 (11) 12 (6) 0.15
Weight status 0.04
Overweight 56 (27) 57 (32)
Obese 96 (46) 57 (32)
Family history of kidney disease 84 (38) 52 (28) 0.03
Hypertension 66 (31) 50 (27) 0.02
Edema 93 (44) 70 (39) 0.30
eGFR, ml/min per 1.73 m2 66 (42, 97) 89 (66, 114) ,0.001
Albumin, g/dl 3.2 (2.6, 3.9) 3.3 (2.5, 4.1) 0.37
Cholesterol, mg/dl 244 (199, 321) 229 (187, 289) 0.07
LDL cholesterol, mg/dl 142 (99, 198) 121 (91, 174) 0.04
Indication for biopsy ,0.001
Proteinuria 143 (64) 107 (57)
Decreased kidney function 47 (21) 24 (13)
SDNS/FRNS 10 (4) 33 (18)
SRNS 4 (2) 11 (6)
Other 21 (9) 13 (7)
UPC, g/g 4.2 (2.1, 7.1) 3.8 (1.3, 8.6) 0.35
Cohort ,0.001
MCD 29 (13) 77 (41)
FSGS 88 (39) 45 (24)
MN 43 (19) 20 (11)
Other 65 (29) 46 (24)
Prior IST exposure by cohort
MCD 20 (69) 64 (83) 0.11
FSGS 22 (25) 28 (62) ,0.001
MN 9 (21) 7 (35) 0.23
Other 27 (42) 14 (30) 0.23
Prior RAAS blockade exposure by cohort
MCD 11 (38) 27 (35) 0.78
FSGS 68 (77) 29 (64) 0.12
MN 38 (88) 15 (75) 0.18
Other 50 (77) 34 (74) 0.72
Prior IST duration, mo 0 (0, 2) 2 (0, 7) ,0.001
Prospective IST exposure by cohort
MCD 17 (57) 66 (86) 0.002
FSGS 27 (31) 32 (71) ,0.001
MN 20 (47) 8 (40) 0.63
Other 32 (49) 24 (52) 0.76
Prospective RAAS blockade exposure by cohort
MCD 14 (48) 33 (43) 0.62
FSGS 69 (78) 34 (76) 0.71
MN 35 (81) 17 (85) 0.73
Other 51 (78) 33 (72) 0.42
Bivariate results from patients with aminimum of one follow-up proteinuria measurement (n=413). Categorical variables are reported
as frequencies and percentages, andP valueswere obtained using a chi-squared test. Continuous variables are reported asmedians and
interquartile ranges, and P values were generated using a Kruskal–Wallis test. Prior medication (IST, RAAS blockade) exposure refers
to medications reported before study baseline visit. SDNS, steroid-dependent nephrotic syndrome; FRNS, frequently relapsing ne-
phrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; UPC, urine protein-to-creatinine ratio;MCD,minimal-change disease;
MN, membranous nephropathy; IST, immunosuppressive therapy; RAAS, renin-angiotensin-aldosterone system.
(Table 4), CRever was associated with a UPC,1 g/g at
the time of kidney biopsy and MCD. There was a signifi-
cant interaction between IST and disease cohort where IST
exposure was associated with CRever for patients with
FSGS. For patients with MN, prior IST was also associated
with an increased likelihood of CRever. CRever was least
likely in individuals with a UPC.3 g/g, FSGS, and no IST.
Variables that were assessed in this Cox model but not
found to be significant predictors of CRever included fam-
ily history, age, weight status, eGFR, and lipid profile.
A sensitivity analysis that excluded patients with IST
before NEPTUNE baseline confirmed the associations be-
tween baseline proteinuria and renal pathology with
CRever (data not shown). A second sensitivity analysis
was conducted with the NEPTUNE cohort stratified by
children (,18 years) and adults ($18 years). While this
analysis was limited by sample size, the findings of pro-
teinuria, pathology cohort, and therapy continued to be
predictors of CRever within each age strata.
Finally, 20 (4.5%) participants reached ESRD during
NEPTUNE follow-up and two (0.4%) had died as of
December 1, 2014. The subset that progressed to ESRD
had a very low eGFR at baseline of 19 ml/min per 1.73 m2
(IQR, 12, 34) and renal pathology diagnosis of FSGS (n=9
[45%]), MN (n=1 [5%]), or other (n=10 [50%]). Two patients
died in the MN cohort, at 28 and 31 days from enrollment, of
pulmonary embolism (n=1) and infection (n=1). Nine kidney
biopsy–associated serious adverse events were reported in
the 554 enrolled patients; these events included broncho-
spasm, hematoma, hemorrhage, and visceral arterial ische-
mia. All patients subsequently recovered from these events.
Discussion
NEPTUNE is the first multisite, prospective study
designed to enroll individuals with proteinuria at the
time of their initial, clinically indicated kidney biopsy along
Figure 3. | Time to complete remission by cohort (unadjusted). Minimal-change disease (MCD) patients were the most likely to reach
complete remission. FSGS, membranous nephropathy (MN), and other glomerulopathies showed similar remission patterns.
pathology varied by patient age (P,0.001), with MCD 
most common in young children and MN most common 
in older adults. FSGS and other diagnosis were present in 
all ages (Figure 2). The other pathology diagnoses in-
cluded IgA nephropathy (n=55 [47%]), immune complex–
mediated glomerulopathy (n=41 [35%]), C1q nephropathy 
(n=5 [4%]), thin basement membrane disease (n=5 [4%]), 
crescentic GN (n=3 [3%]), nodular glomerulosclerosis (n=3 
[3%]), membranoproliferative GN (n=2 [2%], IgM ne-
phropathy (n=2 [2%]), HIV nephropathy (n=2 [2%]), 
thrombotic microangiopathy (n=1 [1%]), interstitial ne-
phritis (n=1 [1%]), postinfectious GN (n=1 [1%]), nephro-
calcinosis (n=1 [1%]), hepatitis C nephropathy (n=1 [1%]), 
sickle cell nephropathy (n=1 [1%]), and nondiagnostic (n=1 
[1%]). Percentages exceed 100% because eight patients had 
multiple coexisting diagnoses. Other pathology diagnoses 
were observed across the age (range, 1–84 years), protein-
uria, and prebiopsy immunosuppression categories. A to-
tal of 17 (3.8%) local pathology diagnoses were changed 
between local and central pathology review on the basis of 
the NEPTUNE research classification and adjudication cri-
teria. Most of these were minor changes between FSGS 
and MCD classification.
Complete Remission and ESRD Outcomes
Table 3 displays the subset of 413 cohort participants 
eligible for the CRever analysis with median duration of 
observation of 19 months (IQR, 11, 30). Of the patients, 118 
(46%) achieved CRever during observation, and 41%
reached CRever by study month 12 (Figure 3). In bivariate 
analysis, individuals with CRever were younger; less 
likely to have a family history of kidney disease; and 
most likely to have MCD, have a higher eGFR, and have 
been exposed to IST before the baseline visit compared 
with the persistent proteinuria group. According to a mul-
tivariable Cox proportional hazards regression analysis
with the characterization of the phenotype, pathology, and
collection of a diverse set of biospecimens (2). Although
NEPTUNE was designed to focus on MCD, FSGS, and
MN, patients with other pathology diagnoses were re-
tained in the cohort to serve as a scientifically relevant
comparison group. This provides an opportunity to iden-
tify common and distinct mechanisms and determinants of
disease progression across multiple proteinuric conditions.
The original enrollment goal of the cohort was 450 partic-
ipants. An expansion of the target cohort was approved to
allow enrollment beyond the original target. Within the initial
554 individuals, eight were excluded because of inadequate
biopsy (1.3%), nine experienced a biopsy-associated adverse
event (1.4%), and 441 completed all enrollment visits and
met eligibility criteria at the time of the data freeze for this
analysis.
Of the cohort, 11% (n=50) had a UPC,1 g/g before kid-
ney biopsy. Within this low-proteinuria group, a signifi-
cant percentage had MCD (30%), FSGS (32%), or MN (6%)
as opposed to other diagnoses (32%). Only 16% of individ-
uals in this low-UPC group were treated with IST before
baseline. For those with prior therapy, the subnephrotic
UPC may indicate partial proteinuria remission. These
findings suggest that renal pathology is identifiable and
kidney biopsy is a valuable diagnostic tool even in the
setting of low-grade proteinuria. The cohort observation
will need to be longer in order to evaluate the long-term
risk for disease progression in this minimal proteinuria
group.
Overall, the distribution of pathology within the NEP-
TUNE cohort was as follows: MCD in 27%, FSGS in 32%,
MN in 15%, and a variety of other renal pathology
diagnoses in 27%. The frequency of MN was less than
expected despite enrollment of participants in 21 academic
centers. The distribution of pathology varied by age, with
MCD most common in childhood, MN most common in
older adulthood, and FSGS and other diagnoses consis-
tently present throughout the age continuum. All renal
pathology categories were represented across all age
groups except for MN, which was absent in children,10
years of age.
When we compared the biopsy distribution in NEP-
TUNE with that in other pathology-based registries and
cohorts in the southeastern United States, Saudi Arabia,
Japan, and Scotland, NEPTUNE had an FSGS fraction
similar to that in Saudi Arabia and Scotland (NEPTUNE,
32%; Saudi Arabia, 28%; Scotland, 28%), a greater fraction
that that in Japan (6%), and a fraction lower than that in the
southeastern United States (46%) (7–10). MCD was more
common in NEPTUNE that in the other registries (NEP-
TUNE, 27%; southeastern United States, 13%; Saudi Arabia,
18%; Japan, 15%; Scotland, 18%). This may be related to the
age distribution of the NEPTUNE cohort (33% children) as
well as the inclusion of "minimal lesion" in the MCD cohort.
MN was present in 10%–15% of these comparison regis-
tries, with the exception of the southeastern United States
with 31%.
Variation in the prevalence of specific glomerular dis-
eases may be due to ancestry, age of the patient sample,
and referral bias resulting from specific academic medical
center expertise. The presence of other kidney diseases in
all NEPTUNE age groups has potential significance for
children, who are often treated empirically with immuno-
suppression before initial kidney biopsy. Pretreatment
biopsy in children as well as adults may identify un-
expected diagnoses with management implications.
A striking finding was that 46% of the cohort achieved a
complete remission, including 75% of patients with MCD,
34% of those with FSGS, 31% of those with MN, and 41% of
those with other diagnoses. Previous publications reported
frequencies of complete remission ranging from 70% to
87% in MCD, 20% to 34% in FSGS, and 60% in MN. This
published MN estimate includes spontaneous remission as
well as remission after therapy (11–14). Frequencies of
complete remission in NEPTUNE were similar for MCD
Table 4. Multivariable Cox proportional hazard models







UPC 1–3 g/g 0.3 (0.2 to 0.5)
UPC.3 g/g 0.3 (0.2 to 0.5)
Cohort
MCD Reference
FSGS 0.2 (0.1 to 0.4)
MN 0.4 (0.2 to 0.9)
Other 0.5 (0.2 to 1.1)
Prior IST exposure (overall) 1.4 (0.9 to 2.2)
Prior IST exposure by cohort
MCD, treated 0.8 (0.3 to 2.2)
MCD, untreated Reference
FSGS, treated 2.5 (1.1 to 5.6)
FSGS, untreated Reference
MN, treated 2.8 (1.0 to 8.2)
MN, untreated Reference




1.3 (0.9 to 2.1)
Prospective IST exposure by
cohort
MCD, treated 1.8 (0.7 to 4.9)
MCD, untreated Reference
FSGS, treated 2.1 (1.0 to 5.1)
FSGS, untreated Reference
MN, treated 0.4 (0.2 to 1.2)
MN, untreated Reference
Other, treated 1.1 (0.6 to 2.1)
Other, untreated Reference
All patients n=413/188 remissions. Lower hazard ratios in-
dicate a lower likelihood of reaching complete remission. Prior
IST exposure refers to medications reported before study
baseline visit. UPC, urine protein-to-creatinine ratio; MCD,
minimal-change disease; MN, membranous nephropathy; IST,
immunosuppression therapy.
aSignificant unadjusted predictors of complete remission
(P,0.05) that were removed during multivariable backward
selection: family history of kidney disease, family history of
hypertension, family history of diabetes, age, weight status
(obese versus normal weight), eGFR, LDL cholesterol, and tri-
glycerides.
peutic targets are needed to improve the precision of
medical care and outcomes for children and adults with
nephrotic syndrome.
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